Eternity in Medical Information -- Medisurf
Search | Web Directory, News, Variable useful Information, PubMed In Medine, All
Category Select :
Items 101 ~ 120 of 26004, Page 6 of 1301
101. Merck to Present New Analyses for JANUVIA® (sitagliptin) and STEGLATRO™ (ertugliflozin), and Real-World Data Studies at the 79th Scientific Sessions of the American Diabetes Association
Real-World Evidence Research to Explore Socioeconomic, Racial and Ethnic Disparities in Diabetes Treatment
05/16/2019 MERCK
102. New ZonePerfect® Keto is 100% #TrueKeto with the Proven Blend of Macros for Effective Results
Abbott's ZonePerfect Keto shakes and powders are formulated with a science-based macronutrient ("macros") ratio of 75% fat, 20% protein and 5% carbohydrates to support ketosis and burn body fat / ZonePerfect Keto helps fulfill a keto lifestyle on the go - offering the only true keto ready-to-drink option available nationwide at major retailers
05/16/2019 Abbott
103. Medtronic Launches Telescope(TM) Guide Extension Catheter to Support Complex Coronary Cases
FDA Cleared and CE Marked, Telescope Enters Global Market with Design Innovations to Enable Smooth Delivery of Coronary Stents and Balloons
05/16/2019 Medtronic
104. New Research from Merck’s Broad Oncology Clinical Development Program to be Presented at 2019 ASCO Annual Meeting
First-Time Data from POLO Trial Evaluating LYNPARZA ® (olaparib) in Germline BRCA-Mutated Metastatic Pancreatic Cancer in Plenary Session and ASCO Press Program / KEYTRUDA ® (pembrolizumab) Five-Year Survival Data in Advanced Non-Small Cell Lung Cancer (NSCLC) from KEYNOTE-001 Trial in ASCO Press Program / Overall Survival Data for KEYTRUDA in Metastatic Renal Cell Carcinoma (RCC), Recurrent/Metastatic Head and Neck Cancer and Advanced Gastric or Gastroesophageal Junction (GEJ) Cancer
05/15/2019 MERCK
105. Smarter research & development to tackle global health priorities
WHO Chief Scientist invites global health R&D community to contribute to the Directory
05/15/2019 WHO
106. Nearly 9 out of 10 College Students with Student Debt Say It''s Important to Find a Company That Offers Loan Relief
The YouGov-Abbott Student Loan Impact Survey shows 87% of those in college or graduating this year with student debt say finding a company with a student loan benefit is important to them / Additionally, over 6 in 10 working adults with student loans would consider switching to a company with a student loan employee benefit
05/15/2019 Abbott
107. Current Legal Cannabis Driving Limits in U.S., Europe Are Ineffective According to Breaking Research in AACC뭩 Clinical Chemistry Journal
New findings, published today in AACC뭩 Clinical Chemistry journal, add to a growing body of evidence suggesting that no legal driving limit for cannabis can catch impaired recreational users without unfairly penalizing unimpaired regular or medicinal users.
05/14/2019 AACC
108. Adopting a healthy lifestyle helps reduce the risk of dementia
New WHO Guidelines recommend specific interventions for reducing the risk of cognitive decline and dementia
05/14/2019 WHO
109. Abbott Partners With NIH On BRAIN Initiative to Advance Research for Neurological Disorders
Partnership with NIH aims to increase understanding and accelerate the application of neurostimulation therapies / The BRAIN Initiative brings together the brightest minds across disciplines to improve the treatment and prevention of brain disorders
05/14/2019 Abbott
110. The Academy recognizes 14 health stories with a 2019 Media Orthopaedic Reporting Excellence (MORE) Award
05/13/2019 American Academy of Orthopaedic Surgeons
111. Medtronic Reveals Results of First-In-Human Study for Investigational Extravascular ICD System
Company to Proceed with Plans for Future Pivotal Study of New ICD System
05/11/2019 Medtronic
112. WHO is establishing technical advisory group and roster of experts on digital health
05/10/2019 WHO
113. Medtronic Enters Into Definitive Agreement to Acquire Titan Spine
(GLOBE NEWSWIRE via COMTEX) --Acquisition Further Accelerates Medtronic''s Strategy to Transform Spinal Procedures and Improve Outcomes Through Complete Procedural Solutions
05/09/2019 Medtronic
114. American Cancer Society Sets Goal to Reduce US Cancer Deaths 40% by 2035
If people didn’t smoke, ate less meat and more fruits and vegetables, exercised more, and followed cancer screening guidelines, the American Cancer Society (ACS) estimates its new challenge goal of reducing cancer deaths by 40% by 2035 could be achieved.
05/09/2019 American Cancer Society
115. Novel Artificial Intelligence Method Predicts Future Risk of Breast Cancer
A new tool using advanced AI methods can predict a woman’s future risk of breast cancer. / Researchers used almost 90,000 screening mammograms from about 40,000 women to train, validate and test the new breast cancer risk-assessment model. / The model performs equally well across diverse races, ages and family histories.
05/07/2019 Radiological Society of North America
116. World’s First Public Museum Dedicated to Vision Reaches Six-month Milestone
With two-thirds of funding goal met, museum set to open in early 2020
05/03/2019 American Academy of Ophthalmology
117. Death Rates from Liver Cancer Are Increasing, Especially in Men with Less Education
Education Trends in Liver Cancer Death Rates / HCV Infection Trends in Liver Cancer Death Rates
04/26/2019 American Cancer Society
118. RSNA Launches Radiology: Cardiothoracic Imaging
The Radiological Society of North America (RSNA) today published the first issue of its new online journal Radiology: Cardiothoracic Imaging.
04/25/2019 Radiological Society of North America
119. Women with Coronary Artery Wall Thickness at Risk for Heart Disease
Researchers used CCTA and Framingham scores to assess coronary artery disease in 62 women and 62 men at low to intermediate risk of heart disease. / Vessel wall thickness, as measured by MRI, was the strongest variable associated with coronary artery disease in women. / The results point to a potential future role for vessel wall thickness measurements in identifying opportunities for early lifestyle changes or treatment.
04/25/2019 Radiological Society of North America
120. Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
04/25/2019 MERCK
   
1 2 3 4 5 6 7 8 9 10
 
경기도 성남시 분당구 구미동 25-1 엘레강스 프라자 ㈜ 메디서프 | Tel : 031-896-0930 | 사업자 등록번호 : 212-81-47247
통신판매신호번호 : 경기 성남 2007-712 | 대표이사 한상욱